Cell to Cure ApS: Financial statements 2020
CVR: 39401975
Source: annual report 2020, Danish Business Authority
01/09/2019 – 31/08/2020
Cell to Cure ApS (CVR 39401975) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK 523,178 and a net result of DKK 405,000. Equity in the 2020 report amounted to DKK 461,770. The solvency ratio was 55%.
- Gross Profit
- DKK 523,178
- Profit/Loss
- DKK 405,000
- Equity
- DKK 461,770
- Total Assets
- DKK 839,135
- Employees
- 0
Official annual report
How creditworthy is Cell to Cure ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreAbout Cell to Cure ApS
Cell to Cure ApS is a Danish company of the type Anpartsselskab based in Birkerød, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Cell2Cure ApS. The management consists of Jens Kastrup, Annette Ekblond and Mandana Haack-Sørensen. The board consists of Anders Østergaard (chair), Annette Ekblond, Jens Kastrup and Mandana Haack-Sørensen. The company's owners include MEDIC ADVICE ApS, Endeavour Cells ApS and Ekblond.ApS. According to the 2025 annual report, the company had an average of 12 employees. In 2025, the company reported a gross profit of DKK -3,076,475 and a net result of DKK -9,792,604. Equity in the 2025 report amounted to DKK -1,179,103.